Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 73963-72-1
Drug Levels and Effects
Summary of Use during Lactation
Because no information is available on the use of cilostazol during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. If it is used by a nursing mother, monitor the infant for bruising and bleeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Cilostazol
CAS Registry Number
73963-72-1
Drug Class
- Breastfeeding
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.[Drug Metab Dispos. 2007]Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M. Drug Metab Dispos. 2007 Oct; 35(10):1730-2. Epub 2007 Jul 23.
- Review Aripiprazole.[Drugs and Lactation Database (...]Review Aripiprazole.. Drugs and Lactation Database (LactMed®). 2006
- 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts.[J Pharmacol Exp Ther. 2008]6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts.Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H. J Pharmacol Exp Ther. 2008 Jul; 326(1):100-4. Epub 2008 Apr 1.
- Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat.[Drug Metab Dispos. 2014]Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat.Wang C, Wang C, Liu Q, Meng Q, Cang J, Sun H, Peng J, Ma X, Huo X, Liu K. Drug Metab Dispos. 2014 Jun; 42(6):996-1007. Epub 2014 Apr 1.
- Review Valsartan.[Drugs and Lactation Database (...]Review Valsartan.. Drugs and Lactation Database (LactMed®). 2006
- Cilostazol - Drugs and Lactation Database (LactMed®)Cilostazol - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...